Elutia Share Price Today
(NASDAQ: ELUT)

Name: Elutia Share Price Today (NASDAQ: ELUT) - Elutia Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Elutia share price is $2.81 & ₹244.38 as on 6 Mar 2025, 2.30 'hrs' IST

$2.81

▲

-0.15

(-5.07%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Elutia share price in Dollar and Rupees. Guide to invest in Elutia stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Elutia, along with analyst recommendations, forecasts, and comprehensive financials.

Elutia share price movements

Today's Low: $2.81
Today's High: $3.02
$2.81
0.0%
Downside
Day's Volatility :6.8%
Upside
6.8%
52 Weeks Low: $2.28
52 Weeks High: $5.24
$2.81
18.86%
Downside
52 Weeks Volatility :56.49%
Upside
46.37%

Elutia (ELUT) Returns

Period	Elutia Inc	Index (Russel 2000)
3 Months	-31.32%	0.0%
6 Months	-26.73%	0.0%
1 Year	-16.15%	0.0%
3 Years	107.94%	-11.6%

Elutia (ELUT) Key Statistics

in dollars & INR

Previous Close	$2.96
Open	$2.93
Today's High	$3.015
Today's Low	$2.81
Market Capitalization	$125.9M
Today's Volume	$3.8K
52 Week High	$5.24
52 Week Low	$2.28
Revenue TTM	$24.8M
EBITDA	$-21.0M
Earnings Per Share (EPS)	$-2.35
Profit Margin	-218.72%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	0.0%

How to invest in Elutia Stock (ELUT) from India?

It is very easy for Indian residents to invest directly in Elutia from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Elutia stock in both Indian Rupees (INR) and US Dollars (USD). Search for Elutia or ELUT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Elutia or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Elutia shares which would translate to 0.309 fractional shares of Elutia as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Elutia, in just a few clicks!

Returns in Elutia (ELUT) for Indian investors in Rupees

The Elutia stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Elutia investment value today

Current value as on today

₹84,566

Returns

₹15,434

(-15.43%)

Returns from Elutia Stock

₹20,397 (-20.4%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Elutia (ELUT)

67%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Elutia Stock from India on INDmoney has increased by 67% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Elutia

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Elutia(by analysts ranked 0 to 5 stars)

Based on 8 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Elutia Stock (ELUT)

What analysts predicted

Upside of 220.28%

Target:

$9.00

Current:

$2.81

Insights on Elutia Stock (Ticker Symbol: ELUT)

Price Movement
In the last 1 month, ELUT stock has moved up by 16.1%
Decreasing Revenue
Revenue is down for the last 3 quarters, 6.69M → 5.92M (in $), with an average decrease of 5.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -28.18M → 1.28M (in $), with an average increase of 2291.3% per quarter
ELUT vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 54.6% return, outperforming this stock by 72.4%
Price to Sales
ForELUT every $1 of sales, investors are willing to pay $3.1, whereas for Boston Scientific Corp., the investors are paying $9.1 for every $1 of sales.

ELUT Elutia Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$42.9M	-
Net Income	$-11.9M	-
Net Profit Margin	-27.83%	-

	FY20	Y/Y Change
Revenue	$42.7M	↓ 0.51%
Net Income	$-21.8M	↑ 82.8%
Net Profit Margin	-51.13%	↓ 23.3%

	FY21	Y/Y Change
Revenue	$47.4M	↑ 11.03%
Net Income	$-24.8M	↑ 13.78%
Net Profit Margin	-52.4%	↓ 1.27%

	FY22	Y/Y Change
Revenue	$23.8M	↓ 49.68%
Net Income	$-32.9M	↑ 32.48%
Net Profit Margin	-137.94%	↓ 85.54%

	FY23	Y/Y Change
Revenue	$24.7M	↑ 3.76%
Net Income	$-37.7M	↑ 14.47%
Net Profit Margin	-152.18%	↓ 14.24%

	Q2 FY23	Q/Q Change
Revenue	$10.3M	↓ 21.1%
Net Income	$-10.6M	↑ 33.2%
Net Profit Margin	-103.16%	↓ 42.06%

	Q3 FY23	Q/Q Change
Revenue	$6.1M	↓ 40.49%
Net Income	$-9.7M	↓ 8.23%
Net Profit Margin	-159.08%	↓ 55.92%

	Q4 FY23	Q/Q Change
Revenue	$5.9M	↓ 4.11%
Net Income	$-15.3M	↑ 57.14%
Net Profit Margin	-260.7%	↓ 101.62%

	Q1 FY24	Q/Q Change
Revenue	$6.7M	↑ 13.94%
Net Income	$-18.0M	↑ 17.48%
Net Profit Margin	-268.81%	↓ 8.11%

	Q2 FY24	Q/Q Change
Revenue	$6.3M	↓ 6.02%
Net Income	$-28.2M	↑ 56.61%
Net Profit Margin	-447.94%	↓ 179.13%

	Q3 FY24	Q/Q Change
Revenue	$5.9M	↓ 5.87%
Net Income	$1.3M	↓ 104.56%
Net Profit Margin	21.72%	↑ 469.66%

	FY19	Y/Y Change
Profit	$19.8M	-

	FY20	Y/Y Change
Profit	$20.6M	↑ 4.01%

	FY21	Y/Y Change
Profit	$19.0M	↓ 7.49%

	FY22	Y/Y Change
Profit	$11.6M	↓ 38.81%

	FY23	Y/Y Change
Profit	$11.1M	↓ 5.03%

	Q2 FY23	Q/Q Change
Profit	$980.0K	↓ 84.52%

	Q3 FY23	Q/Q Change
Profit	$2.8M	↑ 189.9%

	Q4 FY23	Q/Q Change
Profit	$2.1M	↓ 25.24%

	Q1 FY24	Q/Q Change
Profit	$2.8M	↑ 33.85%

	Q2 FY24	Q/Q Change
Profit	$2.8M	↓ 1.55%

	Q3 FY24	Q/Q Change
Profit	$2.7M	↓ 2.07%

	FY19	Y/Y Change
Operating Cash Flow	$-7.2M	-
Investing Cash Flow	$-577.0K	-
Financing Cash Flow	$8.0M	-

	FY20	Y/Y Change
Operating Cash Flow	$-13.4M	↑ 85.95%
Investing Cash Flow	$-640.0K	↑ 10.92%
Financing Cash Flow	$51.0M	↑ 539.39%

	FY21	Y/Y Change
Operating Cash Flow	$-15.6M	↑ 16.25%
Investing Cash Flow	$-369.0K	↓ 42.34%
Financing Cash Flow	$6.9M	↓ 86.51%

	FY22	Y/Y Change
Operating Cash Flow	$-21.9M	↑ 40.24%
Investing Cash Flow	$-540.0K	↑ 46.34%
Financing Cash Flow	$9.0M	↑ 30.8%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-2.4M	↑ 0.0%
Investing Cash Flow	$-85.0K	↑ 0.0%
Financing Cash Flow	$-19.0K	↑ 0.0%

Elutia Technicals Summary

Sell

Neutral

Buy

Elutia is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Elutia (ELUT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Elutia Inc	7.25%	-26.73%	-16.15%	107.94%	107.94%
Medtronic Plc	2.26%	4.07%	8.74%	-12.76%	0.68%
Edwards Lifesciences Corp.	0.07%	8.12%	-19.19%	-34.12%	12.08%
Boston Scientific Corp.	0.07%	27.33%	53.68%	143.5%	203.93%
Stryker Corporation	-0.63%	8.92%	9.84%	53.87%	125.87%
Abbott Laboratories	7.11%	21.64%	15.28%	15.75%	78.63%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Elutia Inc	NA	NA	NA	0.0	0.0	-0.29	NA	-1.16
Medtronic Plc	28.75	28.75	1.87	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.5	30.5	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	83.9	83.9	1.85	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.89	50.89	2.85	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Elutia Inc	Buy	$125.9M	107.94%	NA	-218.72%
Medtronic Plc	Buy	$120.9B	0.68%	28.75	12.83%
Edwards Lifesciences Corp.	Buy	$42.0B	12.08%	30.5	76.75%
Boston Scientific Corp.	Buy	$154.8B	203.93%	83.9	11.07%
Stryker Corporation	Buy	$150.7B	125.87%	50.89	13.25%
Abbott Laboratories	Buy	$238.6B	78.63%	18.34	31.95%

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Organization	Elutia
Employees	54
CEO	Dr. C. Randal Mills Ph.D.
Industry	Miscellaneous

Management People of Elutia

Name	Title
Dr. C. Randal Mills Ph.D.	Co-Founder, President & CEO and Director
Mr. Matthew B. Ferguson	Chief Financial Officer
Dr. Michelle LeRoux Williams Ph.D.	Chief Scientific Officer
Ms. Courtney Guyer	Vice President of Marketing
Dr. Sonali Fonseca Ph.D.	VP & Head of Emerging Businesses
Mr. Jeffry D. Hamet	Senior VP of Finance, Treasurer & Secretary

Important FAQs about investing in ELUT Stock from India :

What is Elutia share price today?

Elutia share price today stands at $2.81, Open: $2.93 ; Previous Close: $2.96 ; High: $3.02 ; Low: $2.81 ; 52 Week High: $5.24 ; 52 Week Low: $2.28.

The stock opens at $2.93, after a previous close of $2.96. The stock reached a daily high of $3.02 and a low of $2.81, with a 52-week high of $5.24 and a 52-week low of $2.28.

Can Indians buy Elutia shares?

Yes, Indians can invest in the Elutia (ELUT) from India.

With INDmoney, you can buy Elutia at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Elutia at zero transaction cost.

How can I buy Elutia shares from India?

It is very easy to buy Elutia from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Elutia (ELUT) be purchased?

Yes, you can buy fractional shares of Elutia with INDmoney app.

What are the documents required to start investing in Elutia stocks?

To start investing in Elutia, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.